Immuron Limited (ASX:IMC)
Australia · Delayed Price · Currency is AUD 0.0400
+0.0080 (25.00%)
Oct 29, 2026, 3:12 PM AEDT
Immuron Revenue
In the fiscal year ending June 30, 2026, Immuron had annual revenue of 7.71M AUD with 5.85% growth. Immuron had revenue of 3.53M in the half year ending June 30, 2026, with 38.55% growth. That makes Immuron the 39,677th largest company in the world by revenue and 761st in Australia.
Revenue
7.71M
Revenue Growth
+5.85%
P/S Ratio
1.34
Revenue / Employee
964.20K
Employees
8
Market Cap
12.91M
Revenue by Geography
- Australia 5.78M 74.9%
- United States (US) 1.77M 22.9%
- Canada 165.67K 2.1%
Fiscal year ended Jun 30, 2026 See the full Immuron breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 7.71M | 426.60K | 5.85% |
| Jun 30, 2025 | 7.29M | 2.38M | 48.63% |
| Jun 30, 2024 | 4.90M | 3.10M | 171.67% |
| Jun 30, 2023 | 1.80M | 1.04M | 135.85% |
| Jun 30, 2022 | 765.19K | 619.42K | 424.91% |
| Jun 30, 2021 | 145.78K | -2.85M | -95.13% |
| Jun 30, 2020 | 2.99M | 604.81K | 25.33% |
| Jun 30, 2019 | 2.39M | 544.52K | 29.55% |
| Jun 30, 2018 | 1.84M | 446.71K | 31.99% |
| Jun 30, 2017 | 1.40M | 395.12K | 39.47% |
| Jun 30, 2016 | 1.00M | -1.30K | -0.13% |
| Jun 30, 2015 | 1.00M | 21.33K | 2.17% |
| Jun 30, 2014 | 981.05K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| EZZ Life Science Holdings | 46.28M |
| Radiopharm Theranostics | 12.87M |
| Argenica Therapeutics | 5.48M |
| Proteomics International Laboratories | 3.37M |
| Imugene | 2.09M |
| Noxopharm | 1.43M |
| Cambium Bio | 1.23M |
| ReNerve | 510.36K |
Immuron News
- 2 days ago - Immuron Limited Announces Q1 Global Sales of AUD$2.2 million - Nasdaq
- 2 days ago - Immuron continued quarterly sales growth - GlobeNewsWire
- 6 days ago - Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference - GlobeNewsWire
- 16 days ago - Immuron Reports Phase 2 Travelan Results Published In Scientific Reports; Stock Down - Nasdaq
- 16 days ago - Immuron’s Travelan Phase 2 study results published - TheFly
- 16 days ago - Travelan® Phase 2 Study Results Published - GlobeNewsWire
- 7 weeks ago - Immuron To Launch PROIBS In U.S. After Australia Debut; Pre-market Shares Up - Nasdaq
- 7 weeks ago - Immuron to launch Proibs in the U.S. - TheFly